Revelation Biosciences (REVB) AI Stock Analysis

• Market Cap: $5.33M
• Dividend Yield: N/A
• Average Volume (3M): 740.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: N/A
• EPS Growth: 96.26%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.77
• Shares Outstanding: 5,924,137
• 10 Day Avg. Volume: 239,834
• 30 Day Avg. Volume: 740,557
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.81
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.21
• Enterprise Value/Market Cap: -0.63
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 0.41
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.85 ▼(-5.56% Downside)

The score is held down primarily by weak financial performance (no revenue, continued losses, and significant cash burn) and bearish technicals (price below all key moving averages with negative MACD). Corporate updates provide some upside from clinical progress, but dilution/runway risk and the lack of profitability keep the overall score low.

Positive Factors

Debt-Free Balance Sheet

Having no debt reduces financial risk and provides flexibility for future investments, which is crucial for a clinical-stage company navigating uncertain revenue streams.

Innovative Product Pipeline

A focus on immunologic-based therapies for unmet medical needs positions the company well in the biotechnology sector, potentially leading to breakthrough treatments and partnerships.

Strategic Partnerships Potential

Potential collaborations with large pharma companies can provide necessary funding and market access, crucial for advancing clinical-stage products towards commercialization.

Negative Factors

Lack of Revenue

The absence of revenue generation is a significant concern, indicating challenges in monetizing the product pipeline and achieving financial sustainability.

Negative Cash Flow

Persistent negative cash flow suggests unsustainable operations without external financing, posing risks to long-term viability and operational continuity.

Persistent Losses

Ongoing losses without a clear path to profitability highlight financial instability and the urgent need for strategic changes to improve financial health.

Revelation Biosciences Business Overview & Revenue Model

Company Description

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

How the Company Makes Money

Revelation Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model may include research and development collaborations, licensing agreements, and potential future product sales. Key revenue streams likely involve partnerships with larger pharmaceutical companies for joint development or commercialization efforts, as well as securing funding through grants or investments to support ongoing research. Currently, as a clinical-stage company, significant earnings may not be realized until products receive regulatory approval and reach the market.

Revelation Biosciences Financial Statement Overview

Summary

Revelation Biosciences faces significant financial challenges with no revenue generation and persistent losses. While the balance sheet is not burdened by debt, the dependence on external financing raises concerns about future liquidity. The ongoing negative cash flow highlights the urgent need for strategic changes to improve financial health.

Income Statement

Revelation Biosciences has no revenue over the reported periods, which is concerning for any growth trajectory. The company consistently reports negative EBIT and net income, indicating ongoing losses with no apparent path to profitability. The absence of revenue growth and negative margins are significant weaknesses.

Balance Sheet

The balance sheet shows a relatively strong equity position with no debt, which reduces financial risk. However, the company has negative net income, impacting the return on equity. The equity ratio is reasonable but challenged by the continual losses and lack of revenue generation.

Cash Flow

The cash flow statement reveals negative operating and free cash flow, which is a red flag for sustainability. The company heavily relies on financing activities to cover cash flow deficiencies, which is not sustainable long-term. The cash flow to net income ratios are unfavorable due to ongoing losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-8.19M	-7.95M	-8.63M	-10.84M	-11.93M	0.00
Net Income	-8.13M	-15.04M	-120.25K	-10.83M	-11.99M	-3.80M
Balance Sheet
Total Assets	12.86M	6.62M	12.21M	5.50M	2.04M	4.62M
Cash, Cash Equivalents and Short-Term Investments	12.71M	6.50M	11.99M	5.25M	1.27M	4.49M
Total Debt	0.00	0.00	0.00	0.00	16.75K	0.00
Total Liabilities	1.85M	1.91M	5.56M	4.45M	2.14M	1.21M
Stockholders Equity	11.00M	4.71M	6.65M	1.05M	-99.47K	3.41M
Cash Flow
Free Cash Flow	-10.03M	-18.34M	-7.29M	-11.22M	-11.22M	-215.07K
Operating Cash Flow	-10.05M	-18.32M	-7.29M	-11.22M	-11.09M	-215.07K
Investing Cash Flow	17.69K	-19.17K	0.00	0.00	-131.96K	-74.04M
Financing Cash Flow	16.20M	12.85M	14.03M	15.20M	8.00M	74.26M

Revelation Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 0.9 is above the 20-day moving average (MA) of 0.88, below the 50-day MA of 0.95, and below the 200-day MA of 3.27, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.90 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.

Revelation Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GTBP	47 Neutral	$7.76M	-0.20	-356.99%	―	―	54.62%
DRMA	44 Neutral	$1.87M	-0.10	-203.36%	―	―	90.53%
REVB	43 Neutral	$5.33M	-0.03	-118.88%	―	―	96.26%
AZTR	43 Neutral	$3.28M	-0.05	-215.04%	―	-100.00%	93.82%

Revelation Biosciences Corporate Events

Revelation Biosciences Extends Stock Warrants Expiration

On December 3, 2025, Revelation Biosciences held a Special Meeting where stockholders approved the issuance of shares related to Class I Common Stock Warrants, extending their expiration to December 3, 2030. The company also provided a corporate update, highlighting the completion of a Phase 1b clinical study for Gemini in CKD patients, showcasing promising results in inflammation treatment. As they prepare for a meeting with the FDA, Revelation Biosciences plans to advance Gemini’s development for acute kidney injury treatment, aiming to start a Phase 2 or Phase 3 clinical study in 2026.

The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.

Revelation Biosciences Reschedules Stockholder Meeting

On October 29, 2025, Revelation Biosciences announced the cancellation of its adjourned Special Meeting of Stockholders due to technical difficulties that prevented stockholders from voting all their shares. The company has rescheduled the meeting for December 3, 2025, and will issue new proxy materials to stockholders. This development may impact the company’s operational timelines and shareholder engagement, as the company encourages prompt voting upon receipt of new materials.

The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.

Revelation Biosciences Adjourns Special Stockholders Meeting

On October 15, 2025, Revelation Biosciences announced the adjournment of its Special Meeting of Stockholders to October 29, 2025, due to insufficient shares present for a quorum. The company encourages all stockholders to participate and vote, emphasizing the importance of their involvement in the decision-making process.

The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.